Autres langues Cabaletta Bio, Inc.

Actions

CABA

US12674W1099

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 22/05/2024			Varia. 5j.	Varia. 1 janv.
11,81 ^USD	-3,12 %		-6,93 %	-47,97 %

15/05	Cabaletta Bio, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
22/03	CABALETTA BIO, INC. : HC Wainwright réitère son opinion positive sur le titre	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cabaletta Bio : Corporate Presentation	15/05
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update	15/05
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	13/05
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	13/05
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	21/03
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment	20/03
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03
North American Morning Briefing : Markets on Hold -2-	20/03
North American Morning Briefing : Stock Futures -2-	13/03
Cabaletta Bio to Participate in Upcoming Investor Conferences in March	27/02
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment	02/02
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment	01/02
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201	01/02
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis	01/02
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201	08/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cabaletta Bio, Inc.

Actions

CABA

US12674W1099

Autres langues

Filtres